{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:48:49Z","timestamp":1775461729351,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04791-8","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T09:39:41Z","timestamp":1764581981000},"page":"6897-6910","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting centromere protein M represses cell growth and mobility via inactivating AKT pathway but less affects BRAF inhibitor sensitivity in cutaneous melanoma"],"prefix":"10.1007","volume":"399","author":[{"given":"Shujie","family":"Ruan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhechen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binlin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youzhi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"1","key":"4791_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, H\u00f6ller C, Lebb\u00e9 C, Lee RJ, Long GV, Lorigan P, Mu\u00f1oz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michielin O, Ascierto PA (2025) Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 36(1):10\u201330","journal-title":"Ann Oncol"},{"key":"4791_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104276","volume":"196","author":"A Boutros","year":"2024","unstructured":"Boutros A, Croce E, Ferrari M, Gili R, Massaro G, Marconcini R, Arecco L, Tanda ET, Spagnolo F (2024) The treatment of advanced melanoma: current approaches and new challenges. Crit Rev Oncol Hematol 196:104276","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"4791_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/mmt.15.21","volume":"2","author":"S Bowyer","year":"2015","unstructured":"Bowyer S, Lee R, Fusi A, Lorigan P (2015) Dabrafenib and its use in the treatment of metastatic melanoma. Melanoma Manag 2(3):199\u2013208","journal-title":"Melanoma Manag"},{"issue":"3","key":"4791_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4791_CR5","first-page":"903","volume":"20","author":"J Chen","year":"2019","unstructured":"Chen J, Wu F, Shi Y, Yang D, Xu M, Lai Y, Liu Y (2019) Identification of key candidate genes involved in melanoma metastasis. Mol Med Rep 20(2):903\u2013914","journal-title":"Mol Med Rep"},{"issue":"12","key":"4791_CR6","first-page":"1838","volume":"65","author":"SC Dougherty","year":"2024","unstructured":"Dougherty SC, Flowers WL, Gaughan EM (2024) Precision oncology in melanoma: changing practices. J Nucl Med 65(12):1838\u20131845","journal-title":"J Nucl Med"},{"issue":"3","key":"4791_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.suc.2024.11.004","volume":"105","author":"S Hollander","year":"2025","unstructured":"Hollander S, Geron V, Rhodin KE, Beasley GM (2025) Adjuvant therapy for melanoma. Surg Clin North Am 105(3):555\u2013568","journal-title":"Surg Clin North Am"},{"key":"4791_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR (2016) The p53 pathway: origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem 85:375\u2013404","journal-title":"Annu Rev Biochem"},{"key":"4791_CR9","unstructured":"Khaddour K, Kurn H, Zito PM (2025) Vemurafenib. StatPearls. StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies"},{"key":"4791_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2741\/1831","volume":"11","author":"L Larue","year":"2006","unstructured":"Larue L, Delmas V (2006) The WNT\/Beta-catenin pathway in melanoma. Front Biosci 11:733\u2013742","journal-title":"Front Biosci"},{"issue":"3","key":"4791_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.det.2025.03.004","volume":"43","author":"DI Latoni","year":"2025","unstructured":"Latoni DI, Kim SH, Tsao H (2025) Systemic therapies for metastatic melanoma. Dermatol Clin 43(3):483\u2013494","journal-title":"Dermatol Clin"},{"issue":"10","key":"4791_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00403-014-1480-8","volume":"306","author":"MS Leo","year":"2014","unstructured":"Leo MS, Sivamani RK (2014) Phytochemical modulation of the Akt\/mTOR pathway and its potential use in cutaneous disease. Arch Dermatol Res 306(10):861\u2013871","journal-title":"Arch Dermatol Res"},{"key":"4791_CR13","doi-asserted-by":"crossref","unstructured":"Lipsick J (2025) A history of cancer research: the P53 pathway. Cold Spring Harb Perspect Med 15(2)","DOI":"10.1101\/cshperspect.a035782"},{"issue":"1","key":"4791_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3724\/abbs.2021013","volume":"54","author":"C Liu","year":"2022","unstructured":"Liu C, Wang Y, Dao Y, Wang S, Hou F, Yang Z, Liu P, Lv J, Lv L, Li G, Zhou Y, Deng Z (2022) Upregulation of CENPM facilitates lung adenocarcinoma progression via PI3K\/AKT\/mTOR signaling pathway. Acta Biochim Biophys Sin (Shanghai) 54(1):99\u2013112","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"2","key":"4791_CR15","volume":"1874","author":"JB Loureiro","year":"2020","unstructured":"Loureiro JB, Abrantes M, Oliveira PA, Saraiva L (2020) P53 in skin cancer: from a master player to a privileged target for prevention and therapy. Biochimica Et Biophysica Acta (BBA) 1874(2):188438","journal-title":"Biochimica Et Biophysica Acta (BBA)"},{"issue":"271","key":"4791_CR16","volume":"2005","author":"RT Moon","year":"2005","unstructured":"Moon RT (2005) Wnt\/beta-catenin pathway. Sci STKE 2005(271):cm1","journal-title":"Sci STKE"},{"issue":"6","key":"4791_CR17","first-page":"2319","volume":"53","author":"GM Nitulescu","year":"2018","unstructured":"Nitulescu GM, Van De Venter M, Nitulescu G, Ungurianu A, Juzenas P, Peng Q, Olaru OT, Gr\u0103dinaru D, Tsatsakis A, Tsoukalas D, Spandidos DA, Margina D (2018) The Akt pathway in oncology therapy and beyond (review). Int J Oncol 53(6):2319\u20132331","journal-title":"Int J Oncol"},{"issue":"10","key":"4791_CR18","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.21037\/tcr-22-491","volume":"11","author":"N Qi","year":"2022","unstructured":"Qi N, Niu Y, Li Z, Xiao L, Tang D, Gao W (2022) The prognostic value and mechanisms of centromere protein M in patients with lung adenocarcinoma. Transl Cancer Res 11(10):3471\u20133490","journal-title":"Transl Cancer Res"},{"issue":"2","key":"4791_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10555-005-1577-9","volume":"24","author":"GP Robertson","year":"2005","unstructured":"Robertson GP (2005) Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24(2):273\u2013285","journal-title":"Cancer Metastasis Rev"},{"issue":"7559","key":"4791_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231\u2013235","journal-title":"Nature"},{"issue":"5","key":"4791_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chmielowski B, DiMaio D, Dronca R, Fields RC, Fleming MD, Galan A, Guild S, Hyngstrom J, Karakousis G, Kendra K, Kiuru M, Lange JR, Lanning R, Logan T, Olson D, Olszanski AJ, Ott PA, Ross MI, Rothermel L, Salama AK, Sharma R, Skitzki J, Smith E, Tsai K, Wuthrick E, Xing Y, McMillian N, Espinosa S (2024) NCCN guidelines\u00ae insights: melanoma: cutaneous, version 2.2024. J Natl Compr Canc Netw 22(5):290\u2013298","journal-title":"J Natl Compr Canc Netw"},{"issue":"D1","key":"4791_CR22","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S, Bork P, Jensen LJ, von Mering C (2023) The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51(D1):D638-d646","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4791_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00603-8","volume":"11","author":"A Tasdogan","year":"2025","unstructured":"Tasdogan A, Sullivan RJ, Katalinic A, Lebbe C, Whitaker D, Puig S, van de Poll-Franse LV, Massi D, Schadendorf D (2025) Cutaneous melanoma. Nat Rev Dis Primers 11(1):23","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"4791_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13046-020-01644-5","volume":"39","author":"S Tian","year":"2020","unstructured":"Tian S, Lou L, Tian M, Lu G, Tian J, Chen X (2020) MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer. Journal of Experimental & Clinical Cancer Research\u202f: CR 39(1):143","journal-title":"Journal of Experimental & Clinical Cancer Research : CR"},{"issue":"1","key":"4791_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12885-023-11808-z","volume":"24","author":"Y Tong","year":"2024","unstructured":"Tong Y, Zhou T, Wang X, Deng S, Qin L (2024) Upregulation of CENPM promotes breast carcinogenesis by altering immune infiltration. BMC Cancer 24(1):54","journal-title":"BMC Cancer"},{"issue":"3","key":"4791_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10735-025-10423-5","volume":"56","author":"L Wu","year":"2025","unstructured":"Wu L, Li J, Wang H, Chang X, Kong Q (2025) Identification of the oncogenic role of centromere protein M in non-small cell lung cancer via CDC20\/MYBL2\/Wnt signaling pathways. J Mol Histol 56(3):144","journal-title":"J Mol Histol"},{"issue":"1","key":"4791_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s13046-019-1444-0","volume":"38","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Najeeb RM, Ma D, Yang K, Zhong Q, Liu Q (2019) Upregulation of CENPM promotes hepatocarcinogenesis through mutiple mechanisms. J Exp Clin Cancer Res\u202f: CR 38(1):458","journal-title":"J Exp Clin Cancer Res : CR"},{"issue":"1","key":"4791_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12885-024-12296-5","volume":"24","author":"W Xie","year":"2024","unstructured":"Xie W, Zhang L, Shen J, Lai F, Han W, Liu X (2024) Knockdown of CENPM activates cGAS-STING pathway to inhibit ovarian cancer by promoting pyroptosis. BMC Cancer 24(1):551","journal-title":"BMC Cancer"},{"issue":"1","key":"4791_CR29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10565-024-09945-7","volume":"41","author":"Z Yi","year":"2024","unstructured":"Yi Z, Jia Y, Lu R, Li C, Wen L, Yin X, Yi J, Li L (2024) E2F1-driven CENPM expression promotes glycolytic reprogramming and tumorigenicity in glioblastoma. Cell Biol Toxicol 41(1):4","journal-title":"Cell Biol Toxicol"},{"issue":"1","key":"4791_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41065-023-00262-3","volume":"160","author":"ZC Zhang","year":"2023","unstructured":"Zhang ZC, Liu YF, Xi P, Nie YC, Sun T, Gong BB (2023) Upregulation of CENPM is associated with poor clinical outcome and suppression of immune profile in clear cell renal cell carcinoma. Hereditas 160(1):1","journal-title":"Hereditas"},{"key":"4791_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216633","volume":"586","author":"J Zhang","year":"2024","unstructured":"Zhang J, Joshua AM, Li Y, O\u2019Meara CH, Morris MJ, Khachigian LM (2024) Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma. Cancer Lett 586:216633","journal-title":"Cancer Lett"},{"key":"4791_CR32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI174415","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Zhang S, Qiu G, Wang X, Yonemura A, Xu H, Cui G, Deng S, Chun J, Chen N, Xu M, Song X, Wang J, Xu Z, Deng Y, Evert M, Calvisi DF, Lin S, Wang H, Chen X (2024) TSC\/mTORC1 mediates mTORC2\/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI174415","journal-title":"J Clin Invest"},{"issue":"1","key":"4791_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70182","volume":"15","author":"C Zou","year":"2025","unstructured":"Zou C, Zhang Y, Liu C, Li Y, Lin C, Chen H, Hou J, Gao G, Liu Z, Yan Q, Su W (2025) Identification of CENPM as a key gene driving adrenocortical carcinoma metastasis via physical interaction with immune checkpoint ligand FGL1. Clin Transl Med 15(1):e70182","journal-title":"Clin Transl Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04791-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:51:30Z","timestamp":1775458290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04791-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4791"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04791-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}